Caxton Associates LLP Invests $531,000 in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Caxton Associates LLP acquired 838 shares of Regeneron Pharmaceuticals, valued at approximately $531,000, during the first quarter of the year.
• Analysts have raised their target prices for Regeneron, with estimates ranging from $640.00 to $850.00, signaling a generally positive outlook for the stock.
• Regeneron recently announced a quarterly dividend of $0.88 per share, reflecting a 0.6% yield and an annualized payout of $3.52.

Caxton Associates LLP acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 838 shares of the biopharmaceutical company's stock, valued at approximately $531,000.

Other institutional investors also recently bought and sold shares of the company. Marietta Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after buying an additional 2,501 shares during the last quarter. Sepio Capital LP boosted its holdings in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after buying an additional 842 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after buying an additional 955 shares during the last quarter. Finally, KBC Group NV boosted its holdings in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after buying an additional 12,793 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on REGN. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Trading Down 1.4%

Shares of REGN stock traded down $8.20 during trading on Friday, hitting $560.00. 602,540 shares of the stock traded hands, compared to its average volume of 942,825. The firm has a market capitalization of $59.35 billion, a P/E ratio of 14.11, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm's fifty day moving average price is $564.61 and its 200-day moving average price is $578.77. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $11.56 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.